<DOC>
	<DOCNO>NCT00575068</DOCNO>
	<brief_summary>The purpose study determine whether anti-CD80 monoclonal antibody ( IDEC-114 ) effective treatment follicular B-cell non-Hodgkin 's lymphoma . This drug never study patient lymphoma , however , studied psoriasis patient various dose level schedule .</brief_summary>
	<brief_title>Safety Efficacy IDEC-114 Treatment Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>Histologically confirm follicular lymphoma relapse failed primary therapy Progressive disease require treatment Bidimensionally measurable disease Acceptable hematologic status Prestudy WHO performance status 0 , 1 , 2 Expected survival &gt; /= 3 month Patients reproductive potential must follow accept birth control method treatment 3 month completion treatment Female patient must pregnant lactating Recovered fully significant toxicity associate prior surgery , radiation treatment , chemotherapy , biological therapy , ABMT , investigational drug Cancer radiotherapy , biological therapy , chemotherapy within 3 week first schedule treatment ( 6 week nitrosourea mitomycinC ) Prednisone immunosuppressive therapy within 3 week first schedule treatment Prior antibody therapy lymphoma ( include radioimmunotherapy ) within 6 month prior first schedule treatment Previous exposure IDEC114 antiCD80 antibody ABMT within 6 month prior first schedule treatment Abnormal liver function Abnormal renal function Presence chronic lymphocytic leukemia ( CLL ) Presence CNS lymphoma Presence HIV infection AIDS Prior diagnosis aggressive nonHodgkin 's lymphoma mantlecell lymphoma Another primary malignancy ( squamous cell basal cell carcinoma skin , situ carcinoma cervix , treated prostate cancer stable PSA ) patient diseasefree least 3 year Serious nonmalignant disease would compromise protocol objective opinion investigator and/or sponsor New York Heart Association Class III IV cardiac disease myocardial infarction within 6 month prior first schedule treatment Major surgery , diagnostic surgery , within 4 week prior first schedule treatment Pleural invasion and/or effusion positive cytology lymphoma Peritoneal invasion and/or ascites positive cytology lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>